Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy

Expert Opinion on Drug Delivery

Volumn 10, Issue 4, 2013, Pages 451-468

  Simon, Manuel ^a,b   Stefan, Nikolas ^b   Plückthun, Andreas ^b   Zangemeister Wittke, Uwe ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antibody drug conjugates; Cancer therapy; EpCAM; Novel binding proteins; Tumor targeting

Indexed keywords

ADECATUMUMAB; ADENOVIRUS VECTOR; ANTIBODY; CATUMAXOMAB; DIPHTHERIA TOXIN; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; IMMUNOGLOBULIN; IMMUNOLIPOSOME; METHOTREXATE; NANOPARTICLE; OPORTUZUMAB MONATOX; PSEUDOMONAS EXOTOXIN; RANPIRNASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER STEM CELL; CARCINOGENESIS; COLON CANCER; CONJUGATE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; EPITHELIUM TUMOR; HUMAN; INTERNALIZATION; MOUSE; NONHUMAN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTOXINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS;

EID: 84875129950     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.759938     Document Type: Review

References (146)

1. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14(3):154-69
2. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006;5(2):147-59
3. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37
4. Bagshawe KD, Sharma SK, Begent RH. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin Biol Ther 2004;4(11):1777-89
5. Moroney S, Plückthun A. Modern antibody technology: The impact on drug development. Modern Biopharmaceuticals: Wiley-VCH Verlag GmbH, Weinheim, Germany; 2008. p. 1147-1186
6. Binz HK, Amstutz P, Plückthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005;23(10):1257-68
7. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346(6287):818-22
8. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249(4968):505-10
9. Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals 2010;3(6):1761-78
10. Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: An immunohistochemical analysis. J Clin Pathol 2011;64(5):415-20
11. Went P, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35(1):122-8
12. Litvinov SV, Velders MP, Bakker HA, et al. Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125(2):437-46
13. Yamashita T, Budhu A, Forgues M, et al. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007;67(22):10831-9
14. Münz M, Kieu C, Mack B, et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23(34):5748-58
15. Maetzel D, Denzel S, Mack B, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11(2):162-71
16. Denzel S, Maetzel D, Mack B, et al. Initial activation of EpCAM cleavage via cell-to-cell contact. BMC Cancer 2009;9:402
17. Chaves-Perez A, Mack B, Maetzel D, et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2012; doi:10.1038/onc.2012.75
18. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med 2007;58:267-84
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983-8
20. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10(20):6897-904
21. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8(5):329-40
22. Schmelzer E, Reid LM. EpCAM expression in normal, non-pathological tissues. Frontiers Biosci 2008;13:3096-100
23. Herlyn M, Steplewski Z, Herlyn D, et al. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76(3):1438-42
24. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96(3):417-23
25. Patriarca C, Macchi RM, Marschner AK, et al. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 2012;38(1):68-75
26. Balzar M, Briaire-de Bruijn I, Rees-Bakker H, et al. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol 2001;21(7):2570-80
27. Chong JM, Speicher DW. Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 2001;276(8):5804-13
28. Kuhn S, Koch M, Nubel T, et al. A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression. Mol Cancer Res 2007;5(6):553-67
29. Balzar M, Winter M, de Boer C, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77(10):699-712
30. Raum T, Gruber R, Riethmüller G, et al. Anti-self antibodies selected from a human IgD heavy chain repertoire: A novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 2001;50(3):141-50
31. Münz M, Murr A, Kvesic M, et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 2010;10:44
32. Stefan N, Martin-Killias P, Wyss-Stoeckle S, et al. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol 2011;413(4):826-43
33. Münz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69(14):5627-9
34. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414(6859):105-11
35. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8(10):755-68
36. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 2009;9(2):143; author reply 43
37. Thurmond LM, Stimmel JB, Ingram AC, et al. Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunol Immunother 2003;52(7):429-37
38. Balzar M, Prins FA, Bakker HA, et al. The structural analysis of adhesions mediated by Ep-CAM. Exp Cell Res 1999;246(1):108-21
39. McLaughlin P, Harmsen MC, Dokter W, et al. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: A new model to study carcinoma-directed immunotherapy. Cancer Res 2001;61(10):4105-11
40. Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95(12):851-67
41. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 2009;21(2):177-84
42. Melnikova I, Golden J. Targeting protein kinases. Nat Rev Drug Discov 2004;3(12):993-4
43. Sankpal NV, Mayfield JD, Willman MW, et al. Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 2011;13(6):R124
44. Hase T, Sato M, Yoshida K, et al. Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. Cancer Sci 2011;102(8):1493-500
45. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64(16):5818-24
46. Chen MW, Hua KT, Kao HJ, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res 2010;70(20):7830-40
47. Shigdar S, Lin J, Yu Y, et al. An RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule (EpCAM). Cancer Sci 2011;102(5):991-8
48. Mitra M, Misra R, Harilal A, et al. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis 2011;17:2724-37
49. Selbo PK, Sivam G, Fodstad O, et al. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin. Int J Cancer 2000;87(6):853-9
50. Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356(9246):1981-2
51. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004;10(9):3131-6
52. Schmidt M, Hasenclever D, Schaeffer M, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res 2008;14(18):5849-55
53. Seligson DB, Pantuck AJ, Liu X, et al. Epithelial cell adhesion molecule (KSA) expression: Pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res 2004;10(8):2659-69
54. Akita H, Nagano H, Takeda Y, et al. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 2011;30(31):3468-76
55. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1(3):313-23
56. Kurtz JE, Dufour P. Adecatumumab: An anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther 2010;10(6):951-8
57. Gruber R, van Haarlem LJ, Warnaar SO, et al. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res 2000;60(7):1921-6
58. Goodwin RA, Tuttle SE, Bucci DM, et al. Tumor-associated antigen expression of primary and metastatic colon carcinomas detected by monoclonal antibody 17-1A. Am J Clin Pathol 1987;88(4):462-7
59. Herlyn D, Sears HF, Ernst CS, et al. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma. Am J Clin Oncol 1991;14(5):371-8
60. Schwartzberg LS. Clinical experience with edrecolomab: A monoclonal antibody therapy for colorectal carcinoma. Crit Rev Oncol Hematol 2001;40(1):17-24
61. Riethmüller G, Schneider-Gadicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343(8907):1177-83
62. Riethmüller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16(5):1788-94
63. Fields AL, Keller A, Schwartzberg L, et al. Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27(12):1941-7
64. Schmoll HJ, Arnold D. When wishful thinking leads to a misty-eyed appraisal: The story of the adjuvant colon cancer trials with edrecolomab. J Clin Oncol 2009;27(12):1926-9
65. Goldberg RM. Lessons learned from the edrecolomab story: How a checkered past became a checkered flag for monoclonal antibodies in colorectal cancer therapy. Onkologie 2005;28(6-7):311-12
66. LoBuglio A, Saleh M, Braddock J, et al. A phase I trial of the humanized anti-EGP40 monoclonal antibody 3622W94 (Abstr. 1562). Proc Am Soc Clin Oncol 1997;16:436
67. de Bono JS, Tolcher AW, Forero A, et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004;10(22):7555-65
68. Marschner N, Ruettinger D, Zugmaier G, et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody Adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int 2010;85(4):386-95
69. Schmidt M, Scheulen ME, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010;21(2):275-82
70. Schmidt M, Ruttinger D, Sebastian M, et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer. Ann Oncol 2012;23(9):2306-13
71. De Leij L, Helrich W, Stein R, et al. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer 1994;57(S8):60-3
72. Willuda J, Honegger A, Waibel R, et al. High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999;59(22):5758-67
73. Hussain S, Plückthun A, Allen TM, et al. Antitumor activity of an epithelial cell adhesion molecule-targeted nanovesicular drug delivery system. Mol Cancer Ther 2007;6(11):3019-27
74. Hussain S, Plückthun A, Allen TM, et al. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 2006;5(12):3170-80
75. Entwistle J, Brown JG, Chooniedass S, et al. Preclinical evaluation of VB6-845: An anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm 2012;27(9):582-92
76. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 2003;9(7):2837-48
77. Heideman DAM, Snijders PJF, Craanen ME, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001;8(5):342-51
78. Zhao HL, Xue C, Du JL, et al. Sustained and cancer cell targeted cytosolic delivery of Onconase results in potent antitumor effects. J Control Release 2012;159(3):346-52
79. Zeidler R, Reisbach G, Wollenberg B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163(3):1246-52
80. Sebastian M, Passlick B, Friccius-Quecke H, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunoly Immunother 2007;56(10):1637-44
81. Ruf P, Kluge M, Jager M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol 2010;69(6):617-25
82. Brischwein K, Schlereth B, Guller B, et al. MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43(8):1129-43
83. Cioffi M, Dorado J, Baeuerle PA, et al. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012;18(2):465-74
84. Binz HK, Stumpp MT, Forrer P, et al. Designing repeat proteins: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol 2003;332(2):489-503
85. Boersma YL, Plückthun A. DARPins and other repeat protein scaffolds: Advances in engineering and applications. Curr Opin Biotechnol 2011;22(6):849-57
86. Binz HK, Amstutz P, Kohl A, et al. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 2004;22(5):575-82
87. Simon M, Zangemeister-Wittke U, Plückthun A. Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries. Bioconj Chem 2012;23(2):279-86
88. Tamaskovic R, Simon M, Stefan N, et al. Designed Ankyrin Repeat Proteins (DARPins) from research to therapy. Methods Enzymol 2011;503:101-34
89. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011;21(1):1-10
90. Mi J, Liu Y, Rabbani ZN, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 2010;6(1):22-4
91. Tang Z, Parekh P, Turner P, et al. Generating aptamers for recognition of virus-infected cells. Clin Chem 2009;55(4):813-22
92. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23(9):1137-46
93. Brumlik MJ, Daniel BJ, Waehler R, et al. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin Drug Deliv 2008;5(1):87-103
94. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconj Chem 2006;17(1):114-24
95. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14(4):529-37
96. Elias DJ, Hirschowitz L, Kline LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res 1990;50(13):4154-9
97. Elias DJ, Kline LE, Robbins BA, et al. Monoclonal antibody KS1/4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am J Respir Crit Care Med 1994;150(4):1114-22
98. Froesch BA, Stahel RA, Zangemeister-Wittke U. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small-cell lung cancer cells. Cancer Immunol Immunother 1996;42(1):55-63
99. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261(5118):212-15
100. Sapra P, Hooper AT, O'Donnell CJ, et al. Investigational antibody drug conjugates for solid tumors. Expert Opin Inv Drug 2011;20(8):1131-49
101. Lopus M, Oroudjev E, Wilson L, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 2010;9(10):2689-99
102. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29(4):398-405
103. Krop IE, Lorusso P, Miller KD, et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30(26):3234-41
104. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012
105. Kovtun YVY, Audette CAC, Mayo MFM, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70(6):2528-37
106. Moldenhauer G, Salnikov AV, Lüttgau S, et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 2012;104(8):622-34
107. Lindell TJ, Weinberg F, Morris PW, et al. Specific inhibition of nuclear RNA polymerase II by alpha-amanitin. Science 1970;170(3956):447-9
108. Houba PH, Boven E, van der Meulen-Muileman IH, et al. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate. Int J Cancer 2001;91(4):550-4
109. de Graaf M, Boven E, Oosterhoff D, et al. A fully human anti-Ep-CAM scFvbeta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer 2002;86(5):811-18
110. Oosterhoff D, Pinedo HM, van der Meulen IH, et al. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Br J Cancer 2002;87(6):659-64
111. Oosterhoff D, Overmeer RM, de Graaf M, et al. Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. Br J Cancer 2005;92(5):882-7
112. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA 2000;97(15):8548-53
113. Onda M, Beers R, Xiang L, et al. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 2008;105(32):11311-16
114. Weldon JE, Pastan I. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS 2011;278(23):4683-700
115. Pastan II. Immunotoxins containing Pseudomonas exotoxin A: A short history. Cancer Immunol Immunother 2003;52(5):338-41
116. Engebraaten O, Sivam G, Juell S, et al. Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 2000;88(6):970-6
117. Zimmermann S, Wels W, Froesch BA, et al. A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer. Cancer Immunol Immunother 1997;44(1):1-9
118. Heine M, Freund B, Nielsen P, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS ONE 2011;7(5):e36258-e58
119. Premsukh A, Lavoie JM, Cizeau J, et al. Development of a GMP Phase III purification process for VB4-845, an immunotoxin expressed in E. coli using high cell density fermentation. Protein Expr Purif 2011;78(1):27-37
120. Cizeau JJ, Grenkow DMD, Brown JGJ, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother 2009;32(6):574-84
121. Ewert S, Honegger A, Plückthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004;34(2):184-99
122. Martin-Killias P, Stefan N, Rothschild S, et al. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 2011;17(1):100-10
123. Bremer E, Samplonius D, Kroesen BJ, et al. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 2004;6(5):636-45
124. Bremer EE, Kuijlen JJ, Samplonius DD, et al. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004;109(2):281-90
125. Tolcher AW, Mita M, Meropol NJ, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25(11):1390-5
126. Greco FA, Bonomi P, Crawford J, et al. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61(1):82-90
127. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12(3):228-37
128. Ardelt W, Mikulski SM, Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 1991;266(1):245-51
129. Chao TY, Lavis LD, Raines RT. Cellular uptake of ribonuclease A relies on anionic glycans. Biochemistry 2010;49(50):10666-73
130. Rutkoski TJ, Raines RT. Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol 2008;9(3):185-9
131. Wu Y, Mikulski SM, Ardelt W, et al. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 1993;268(14):10686-93
132. Rodríguez M, Torrent G, Bosch M, et al. Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 2007;120(8):1405-11
133. Dhalluin X, Scherpereel A. Chemotherapy and radiotherapy for mesothelioma. Recent Results Cancer Res 2011;189:127-47
134. Andersen JT, Daba MB, Berntzen G, et al. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010;285(7):4826
135. Connor J, Felder M, Hank J, et al. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 2004;27(3):211-19
136. Ko YJ, Bubley GJ, Weber R, et al. Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKSIL2): Results of a phase I trial in patients with prostate cancer. J Immunother 2004;27(3):232-9
137. Johnson EE, Yamane BH, Buhtoiarov IN, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res 2009;15(15):4875-84
138. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303(5665):1818-22
139. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000;65(1-2):271-84
140. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8(10):2861-71
141. van Zanten J, Doornbos-Van der Meer B, Audouy S, et al. A nonviral carrier for targeted gene delivery to tumor cells. Cancer Gene Ther 2004;11(2):156-64
142. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
143. Winkler J, Martin-Killias P, Plückthun A, et al. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009;8(9):2674-83
144. Haisma HJ, Pinedo HM, Rijswijk A, et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 1999;6(8):1469-74
145. Dreier B, Mikheeva G, Belousova N, et al. Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting. J Mol Biol 2011;405(2):410-26
146. Kawashima R, Abei M, Fukuda K, et al. EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. Int J Cancer 2011;129(5):1244-53